In Brief: Neuropsychiatric Events with Montelukast
Date: May 4, 2020
Issue #:
1597Summary:
The FDA is requiring stronger warnings in the labeling of
the leukotriene receptor antagonist montelukast (Singulair,
and generics) about the risk of suicidal behavior and other
serious neuropsychiatric events associated with its use.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Accolate Allergic rhinitis Allergies Antihistamines Asthma corticosteroids Drug Safety Montelukast Singulair Zafirlukast Zileuton Zyflo Source Type: research
More News: Accolate | Allergy | Allergy & Immunology | Asthma | Brain | Corticosteroid Therapy | Depression | Drugs & Pharmacology | Hay Fever | Neurology | Singulair | Suicide | Warnings